Phthalazinone derivatives

Compounds of the formula (I):wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X═NRX then n is 1 or 2 and if X═CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocycl...

Full description

Saved in:
Bibliographic Details
Main Authors Matthews, Ian Timothy Williams, Smith, Graeme Cameron, Cockcroft, Xiao-Ling Fan, Menear, Keith Allan, Loh, Vincent Junior M, Martin, Niall Morrison Barr, Kerrigan, Frank, Ashworth, Alan, Jackson, Stephen Philip
Format Patent
LanguageEnglish
Published 22.10.2019
Subjects
CHEMISTRY
ELECTROTHERAPY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MAGNETOTHERAPY
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
RADIATION THERAPY
ULTRASOUND THERAPY
Online AccessGet full text

Cover

More Information
Summary:Compounds of the formula (I):wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X═NRX then n is 1 or 2 and if X═CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are both hydrogen, or when X is CRXRY, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R1 is selected from H and halo.
Bibliography:Application Number: US201815904883